Ranbaxy Laboratories Ltd.’s $500 million settlement of criminal and civil allegations involving data fraud and drug manufacturing violations lifts a cloud over the Indian generic drug maker, but the firm still faces a host of operational and regulatory hurdles created by an FDA consent decree.
On May 13, the U.S. Justice Department announced that Ranbaxy had agreed to pay $350 million to settle civil claims brought under the federal False Claims Act and related state laws. The company also agreed to pay a criminal fine of $130 million and forfeit an additional $20 million, with its Ranbaxy USA Inc
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?